Aspen Group Stock

Aspen Group EV/EBIT

The EV/EBIT (Enterprise Value to EBIT) of Aspen Group (APZ.AX) as of Aug 12, 2026 is 32.56. In the previous year, EV/EBIT (Enterprise Value to EBIT) was 44.81 — a change of -27.33% (lower).

EV/EBIT

32.56

YoY

-27.33%

Last updated:

EV/EBIT (Enterprise Value to EBIT) of Aspen Group is 2026 32.56 . EV/EBIT (Enterprise Value to EBIT) of Aspen Group was 2025 44.81 . It decreases by -27.33% lower compared to the previous year.

The Aspen Group EV/EBIT history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

PRICE-TO-EBIT
Date
PRICE-TO-EBIT
Jan 1, 2019
24.14 base
Jan 1, 2020
16.76 base
Jan 1, 2021
32.26 base
Jan 1, 2022
28.13 base
Jan 1, 2023
16.37 base
Jan 1, 2024
17.44 base
Jan 1, 2025
32.23 base
Jan 1, 2026 (e)
15.73 base
YEARPRICE-TO-EBIT
2026 est 15.73
2025 32.23
2024 17.44
2023 16.37
2022 28.13
2021 32.26
2020 16.76
2019 24.14
2018 35.31
2017 -573.47
2016 -15.73
2015 -43.35
2014 56.64
2013 5.98
2012 -53.75
2011 8.40
2010 11.96
2009 61.94
2008 3.08
2007 5.86
2006 5.72
Access this data via the Eulerpool API

Aspen Group Valuation

Details

Historical Valuation Multiples

Price-to-Earnings Ratio (P/E)

The P/E ratio divides Aspen Group's share price by its earnings per share. It tells you how many years of current earnings you are "paying for" when you buy the stock. A P/E of 20 means you pay $20 for every $1 of annual earnings. The S&P 500 historically trades at an average P/E of roughly 15–17. A P/E significantly above that may signal high growth expectations; one below may indicate undervaluation — or declining business quality.

Price-to-Sales Ratio (P/S)

The P/S ratio divides market capitalization by total revenue. Unlike the P/E ratio, it works even for companies that are not yet profitable, making it essential for evaluating high-growth firms. A P/S below 1.0 may indicate undervaluation, while ratios above 10 are typically reserved for fast-growing tech or SaaS companies with high expected future margins.

Price-to-EBIT Ratio

This ratio relates Aspen Group's market price to its operating earnings, excluding the effects of debt structure and tax jurisdiction. It is particularly useful for comparing companies across different countries or with different levels of leverage, because it focuses purely on operational profitability. Lower values suggest cheaper operational earnings.

How to Use This Chart

This chart plots Aspen Group's valuation multiples over time. Compare the current P/E, P/S, and P/EBIT to their own historical averages — if the current ratio is well below the multi-year average, the stock may be relatively cheap compared to its own track record. Combine this with industry comparisons: a P/E that looks high in absolute terms may be justified if Aspen Group grows earnings faster than its peers.

Aspen Group Stock analysis

What does Aspen Group do? Aspen Group Ltd is a globally active pharmaceutical company headquartered in Durban, South Africa. The company's history dates back to 1850, when the first pharmacy was opened by a man named William Charles in Durban. In 1997, Aspen Group Ltd was founded, which continued William Charles' business and expanded strongly in the following years. Aspen's business model is based on the acquisition of pharmaceutical companies and their products, as well as the production of generics and branded drugs. The company operates worldwide and has offices in over 50 countries. Aspen specializes in the fields of thrombosis, anesthesia, oncology, infectious diseases, and nervous system disorders. The various divisions of Aspen include Aspen Global Commercial, Aspen Pharmacare, Aspen Nutritionals, Aspen Oss, Aspen Business Europe, and Aspen Healthcare. Aspen Global Commercial is responsible for the sale of products in various regions of the world. Aspen Pharmacare is engaged in the production and sale of generics and branded drugs. Aspen Nutritionals produces dietary supplements and baby food. Aspen Oss manufactures and distributes bone substitute materials. Aspen Business Europe is responsible for product distribution in Europe, and Aspen Healthcare operates hospitals and health centers in South Africa. Aspen offers a variety of products, including anticoagulants, anesthetics, antibiotics, cancer drugs, HIV/AIDS medications, as well as dietary supplements and baby food. In the field of thrombosis, the company offers a wide range of anticoagulants, such as the active ingredients heparin, enoxaparin, and fondaparinux. In the field of oncology, Aspen produces drugs for the treatment of breast cancer, colon cancer, and lung cancer. Aspen's products are utilized by many different customers worldwide, including government agencies, hospitals, pharmacies, and retailers. Aspen places great emphasis on the quality of its products and has implemented a quality management system to ensure that the products meet the highest standards. In recent years, there have been controversies surrounding Aspen, particularly regarding drug pricing. In 2016, Aspen was fined €5.2 million by the European Commission for charging unreasonably high prices for cancer drugs in five European countries. Aspen has denied the allegations and announced plans to appeal the decision. Despite these controversies, Aspen remains an important player in the global pharmaceutical market. The company has a wide range of products and operates in various regions of the world. Aspen is committed to improving the health and well-being of people and continuously works to develop innovative and effective medications. Aspen Group is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Aspen Group stock

EV/EBIT (Enterprise Value to EBIT) of Aspen Group is 32.56 in 2026.

EV/EBIT (Enterprise Value to EBIT) of Aspen Group changed from 44.81 to 32.56, representing a -27.33% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EV/EBIT (Enterprise Value to EBIT) Aspen Group since 2006 – with annual values, charts, and detailed analysis.

The EV/EBIT ratio measures a company's enterprise value relative to its operating earnings. It accounts for debt, making it useful for comparing companies with different capital structures.

EV/EBIT = Enterprise Value / Earnings Before Interest and Taxes

To evaluate EV/EBIT (Enterprise Value to EBIT)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EV/EBIT (Enterprise Value to EBIT).

A 'good' varies by industry and company stage. On Eulerpool, you can compare EV/EBIT (Enterprise Value to EBIT)'s Aspen Group with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

Valuation — Aspen Group

All Key Metrics — Aspen Group